iRadimed (NASDAQ:IRMD) Issues FY 2025 Earnings Guidance

Key Points

• iRadimed has updated its FY 2025 earnings guidance, projecting earnings per share (EPS) between 1.760-1.860 and revenue of $80.0 million-$82.5 million, exceeding consensus estimates.
• The company recently announced a quarterly dividend of $0.17 per share, translating to an annual yield of 1.2%.
• Wall Street has upgraded iRadimed's stock from a "buy" to a "strong-buy" rating, reflecting increased confidence among analysts.

iRadimed (NASDAQ:IRMD - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.760-1.860 for the period, compared to the consensus estimate of 1.735. The company issued revenue guidance of $80.0 million-$82.5 million, compared to the consensus revenue estimate of $79.4 million. iRadimed also updated its Q3 2025 guidance to 0.450-0.490 EPS.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded iRadimed from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 6th.

iRadimed Stock Down 0.1%

iRadimed stock opened at $58.34 on Friday. The stock has a market cap of $742.08 million, a price-to-earnings ratio of 37.64 and a beta of 0.91. iRadimed has a 12-month low of $42.34 and a 12-month high of $63.29. The business's 50-day simple moving average is $58.21 and its 200 day simple moving average is $55.80.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Tuesday, May 20th were paid a dividend of $0.17 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $0.68 annualized dividend and a yield of 1.2%. iRadimed's dividend payout ratio (DPR) is presently 43.87%.

Institutional Investors Weigh In On iRadimed

Several large investors have recently modified their holdings of IRMD. Royal Bank of Canada boosted its holdings in shares of iRadimed by 14.7% in the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock valued at $1,354,000 after buying an additional 3,307 shares during the period. AQR Capital Management LLC raised its stake in shares of iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock valued at $831,000 after purchasing an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after purchasing an additional 234 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock worth $591,000 after buying an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock worth $8,889,000 after buying an additional 1,821 shares during the period. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.